Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
58
STOK Quote, Financials, Valuation and Earnings
Last price:
$34.28
Seasonality move
:
28.03%
Day range:
$30.68 - $34.67
52-week range:
$5.35 - $38.69
Dividend yield:
0%
P/E ratio:
52.08x
P/S ratio:
9.75x
P/B ratio:
6.37x
Volume:
1.2M
Avg. volume:
686.7K
1-year change:
269.57%
Market cap:
$2B
Revenue:
$36.6M
EPS (TTM):
$0.66
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
|
$5.3M | -$0.72 | -97.14% | -292.94% | $41.89 |
|
BIIB
Biogen, Inc.
|
$2.2B | $1.62 | -4.12% | 85.69% | $205.52 |
|
INSM
Insmed, Inc.
|
$264M | -$1.17 | 205.93% | -30.22% | $213.11 |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$141.8M | $0.06 | 33.77% | -95% | $116.09 |
|
MRNA
Moderna, Inc.
|
$623.9M | -$2.64 | 123.13% | -16.64% | $41.75 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.25% | 39.47% | $28.56 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
|
$34.37 | $41.89 | $2B | 52.08x | $0.00 | 0% | 9.75x |
|
BIIB
Biogen, Inc.
|
$192.08 | $205.52 | $28.2B | 21.81x | $0.00 | 0% | 2.96x |
|
INSM
Insmed, Inc.
|
$161.00 | $213.11 | $34.3B | -- | $0.00 | 0% | 52.80x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$105.49 | $116.09 | $5.4B | -- | $0.00 | 0% | 11.39x |
|
MRNA
Moderna, Inc.
|
$49.70 | $41.75 | $19.4B | -- | $0.00 | 0% | 9.95x |
|
PFE
Pfizer Inc.
|
$26.86 | $28.56 | $152.7B | 19.82x | $0.43 | 6.4% | 2.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
|
1.53% | 2.505 | 0.37% | 6.17x |
|
BIIB
Biogen, Inc.
|
26.72% | 0.777 | 25.77% | 1.70x |
|
INSM
Insmed, Inc.
|
50.57% | 2.488 | 2.04% | 3.35x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
52.19% | 1.284 | 8.47% | 3.01x |
|
MRNA
Moderna, Inc.
|
12.74% | 0.952 | 10.96% | 3.01x |
|
PFE
Pfizer Inc.
|
39.94% | 0.402 | -- | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
|
$9.6M | -$43.1M | 13.73% | 13.95% | -405.3% | -$30.5M |
|
BIIB
Biogen, Inc.
|
$1.5B | $372.1M | 5.34% | 7.36% | 17.06% | $401.7M |
|
INSM
Insmed, Inc.
|
$217.7M | -$249.7M | -77.98% | -192.35% | -94.64% | -$294.2M |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$107.4M | $2.6M | -7.32% | -16.73% | 1.96% | $39.5M |
|
MRNA
Moderna, Inc.
|
$226M | -$857M | -26.84% | -29.19% | -126.4% | $912M |
|
PFE
Pfizer Inc.
|
$12.3B | $3.7B | 5.07% | 10.84% | 21.01% | $4B |
Stoke Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns STOK or BIIB?
Biogen, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -2.24%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Biogen, Inc.'s return on equity of 7.36%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M BIIBBiogen, Inc.68.12% -$0.33 $24.9B -
What do Analysts Say About STOK or BIIB?
Stoke Therapeutics, Inc. has a consensus price target of $41.89, signalling upside risk potential of 21.88%. On the other hand Biogen, Inc. has an analysts' consensus of $205.52 which suggests that it could grow by 7%. Given that Stoke Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.10 0 0 BIIBBiogen, Inc.14 19 1 -
Is STOK or BIIB More Risky?
Stoke Therapeutics, Inc. has a beta of 1.101, which suggesting that the stock is 10.054% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.160, suggesting its less volatile than the S&P 500 by 84.033%.
-
Which is a Better Dividend Stock STOK or BIIB?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or BIIB?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Biogen, Inc. quarterly revenues of $2.2B. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Biogen, Inc.'s net income of -$48.9M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 52.08x while Biogen, Inc.'s PE ratio is 21.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 9.75x versus 2.96x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.9.75x 52.08x $10.6M -$38.3M BIIBBiogen, Inc.2.96x 21.81x $2.2B -$48.9M
-
Which has Higher Returns STOK or INSM?
Insmed, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -124.5%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Insmed, Inc.'s return on equity of -192.35%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M INSMInsmed, Inc.82.51% -$1.54 $1.5B -
What do Analysts Say About STOK or INSM?
Stoke Therapeutics, Inc. has a consensus price target of $41.89, signalling upside risk potential of 21.88%. On the other hand Insmed, Inc. has an analysts' consensus of $213.11 which suggests that it could grow by 33.15%. Given that Insmed, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than Stoke Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.10 0 0 INSMInsmed, Inc.17 1 0 -
Is STOK or INSM More Risky?
Stoke Therapeutics, Inc. has a beta of 1.101, which suggesting that the stock is 10.054% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.
-
Which is a Better Dividend Stock STOK or INSM?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or INSM?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 52.08x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 9.75x versus 52.80x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.9.75x 52.08x $10.6M -$38.3M INSMInsmed, Inc.52.80x -- $263.8M -$328.5M
-
Which has Higher Returns STOK or MIRM?
Mirum Pharmaceuticals, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 2.18%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Mirum Pharmaceuticals, Inc.'s return on equity of -16.73%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M -
What do Analysts Say About STOK or MIRM?
Stoke Therapeutics, Inc. has a consensus price target of $41.89, signalling upside risk potential of 21.88%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $116.09 which suggests that it could grow by 10.05%. Given that Stoke Therapeutics, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Mirum Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.10 0 0 MIRMMirum Pharmaceuticals, Inc.8 0 0 -
Is STOK or MIRM More Risky?
Stoke Therapeutics, Inc. has a beta of 1.101, which suggesting that the stock is 10.054% more volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.821%.
-
Which is a Better Dividend Stock STOK or MIRM?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or MIRM?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Mirum Pharmaceuticals, Inc. quarterly revenues of $133M. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Mirum Pharmaceuticals, Inc.'s net income of $2.9M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 52.08x while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 9.75x versus 11.39x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.9.75x 52.08x $10.6M -$38.3M MIRMMirum Pharmaceuticals, Inc.11.39x -- $133M $2.9M
-
Which has Higher Returns STOK or MRNA?
Moderna, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -121.83%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Moderna, Inc.'s return on equity of -29.19%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M MRNAModerna, Inc.33.33% -$2.11 $9.9B -
What do Analysts Say About STOK or MRNA?
Stoke Therapeutics, Inc. has a consensus price target of $41.89, signalling upside risk potential of 21.88%. On the other hand Moderna, Inc. has an analysts' consensus of $41.75 which suggests that it could fall by -16%. Given that Stoke Therapeutics, Inc. has higher upside potential than Moderna, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.10 0 0 MRNAModerna, Inc.2 17 1 -
Is STOK or MRNA More Risky?
Stoke Therapeutics, Inc. has a beta of 1.101, which suggesting that the stock is 10.054% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.
-
Which is a Better Dividend Stock STOK or MRNA?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or MRNA?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Moderna, Inc. quarterly revenues of $678M. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Moderna, Inc.'s net income of -$826M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 52.08x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 9.75x versus 9.95x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.9.75x 52.08x $10.6M -$38.3M MRNAModerna, Inc.9.95x -- $678M -$826M
-
Which has Higher Returns STOK or PFE?
Pfizer Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -9.34%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M PFEPfizer Inc.69.97% -$0.29 $154.8B -
What do Analysts Say About STOK or PFE?
Stoke Therapeutics, Inc. has a consensus price target of $41.89, signalling upside risk potential of 21.88%. On the other hand Pfizer Inc. has an analysts' consensus of $28.56 which suggests that it could grow by 6.89%. Given that Stoke Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings STOKStoke Therapeutics, Inc.10 0 0 PFEPfizer Inc.7 16 1 -
Is STOK or PFE More Risky?
Stoke Therapeutics, Inc. has a beta of 1.101, which suggesting that the stock is 10.054% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.
-
Which is a Better Dividend Stock STOK or PFE?
Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.4% to investors and pays a quarterly dividend of $0.43 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.
-
Which has Better Financial Ratios STOK or PFE?
Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 52.08x while Pfizer Inc.'s PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 9.75x versus 2.45x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STOKStoke Therapeutics, Inc.9.75x 52.08x $10.6M -$38.3M PFEPfizer Inc.2.45x 19.82x $17.6B -$1.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
